Imatinib Eg (Imatinib)

• Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, making it valuable in several hematologic and solid‑tumor indications.
• Chronic myeloid leukemia: reduces disease progression and improves survival by inhibiting BCR‑ABL‑positive leukemic cells.
• Acute lymphoblastic leukemia: contributes to remission when combined with chemotherapy by targeting BCR‑ABL rearrangements.
• Gastrointestinal stromal tumor: blocks c‑KIT and PDGFR signaling, limiting tumor growth and metastasis.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts proliferative signaling cascades, induces apoptosis of malignant cells, and curtails angiogenesis, providing a targeted anticancer effect without affecting normal cells that lack these activated kinases.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or periorbital area.
• Muscle cramps or pain: often in the limbs.
• Fatigue: general tiredness or weakness.
• Diarrhea: loose stools, sometimes watery.
• Rash: skin redness or itching.

Serious or Rare Side Effects

• Neutropenia: dangerously low white‑blood‑cell count.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Pulmonary hypertension: increased pressure in lung arteries.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Imatinib requires careful monitoring and patient education before and during therapy.

• Blood monitoring: regular CBC and liver‑function tests to detect hematologic or hepatic toxicity.
• Cardiac assessment: evaluate baseline cardiac function and monitor for signs of heart failure.
• Drug interactions: review concomitant medications, especially CYP3A4 modulators.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks.
• Storage: Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Imatinib may interact with several drug classes, necessitating dose adjustments or avoidance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure and toxicity.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce plasma concentrations, compromising efficacy.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding; monitor INR closely.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., midazolam, statins): may require dose modification.
• QT‑prolonging agents (e.g., macrolide antibiotics): increase risk of cardiac arrhythmias.
• Vaccines (live attenuated): potential reduced immunogenicity; consider timing of administration.